Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Context-specific synthetic T cell promoters from assembled transcriptional elements.
Appelbaum J, Wei J, Mukherjee R, Ishida T, Rosser J, Saxby C, Chase J, Carlson M, Sather C, Rahfeldt W, Meechan M, Baldwin M, Flint L, Spurrell C, Gustafson J, Johnson A, Jensen M. Appelbaum J, et al. Res Sq [Preprint]. 2023 Oct 17:rs.3.rs-3339290. doi: 10.21203/rs.3.rs-3339290/v1. Res Sq. 2023. PMID: 37886484 Free PMC article. Preprint.
Second chances for secondary AML.
Appelbaum JS, Appelbaum FR, Percival ME. Appelbaum JS, et al. Blood Adv. 2024 Aug 13;8(15):4221-4222. doi: 10.1182/bloodadvances.2024013318. Blood Adv. 2024. PMID: 39136970 Free PMC article. No abstract available.
A cure for the kiss of death?
Appelbaum JS, Percival ME, Scott BL. Appelbaum JS, et al. Blood Adv. 2025 Jun 10;9(11):2855-2856. doi: 10.1182/bloodadvances.2025015850. Blood Adv. 2025. PMID: 40493363 Free PMC article. No abstract available.
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Halpern AB, Rodríguez-Arbolí E, Othus M, Garcia KA, Percival MM, Cassaday RD, Oehler VG, Becker PS, Appelbaum JS, Abkowitz JL, Orozco JJ, Keel SB, Hendrie PC, Scott BL, Ghiuzeli MC, Estey EH, Walter RB. Halpern AB, et al. Among authors: appelbaum js. Blood Adv. 2023 Sep 12;7(17):4950-4961. doi: 10.1182/bloodadvances.2023010392. Blood Adv. 2023. PMID: 37339483 Free PMC article. Clinical Trial.
Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Wuliji N, Jones SMW, Gooley T, Gerds AT, Medeiros BC, Shami PJ, Galvin J, Adekola K, Luger S, Baer MR, Rizzieri D, Wildes TM, Wang ES, Sekeres MA, Mukherjee S, Smith J, Garrison M, Kojouri K, Appelbaum J, Percival ME, Sandmaier BM, Lee S, Appelbaum FR, Rouce R, Sorror ML. Wuliji N, et al. Among authors: appelbaum j, appelbaum fr. Blood. 2025 Jun 19;145(25):3041-3051. doi: 10.1182/blood.2024027543. Blood. 2025. PMID: 40067123
Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.
Raychaudhuri S, Gooley TA, Rasmussen A, Quach K, Gill E, Halpern AB, Appelbaum JS, Ghiuzeli CM, Hendrie PC, Cassaday RD, Walter RB, Percival MM. Raychaudhuri S, et al. Among authors: appelbaum js. Blood Neoplasia. 2025 Mar 3;2(3):100085. doi: 10.1016/j.bneo.2025.100085. eCollection 2025 Aug. Blood Neoplasia. 2025. PMID: 40535475 Free PMC article.
103 results